FaCT Trial (Facilitated Cascade Testing Trial)

Launched by WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY · Oct 27, 2020

Keywords

ClinConnect Summary

The FaCT Trial is a research study designed to help families understand their risk for certain types of cancer related to BRCA1 and BRCA2 gene mutations. The trial is looking at whether a special approach, which includes support from a medical navigator, an educational video, and easier access to genetic testing, can help more family members get tested compared to the usual care. Participants in the study will be first-degree relatives (like parents, siblings, or children) of patients with these mutations. They will either receive the new support program or the standard care that's currently available. The main goal is to see if this new approach encourages more family members to complete genetic testing within six months.

To be eligible for the trial, participants need to be at least 18 years old, speak and read either English or Spanish, and be patients at specific hospitals or cancer centers. They must also have a relative with a BRCA mutation who is willing to join the study. Participants will receive guidance and information throughout the process, making it easier for them to understand their own risks and the importance of testing for their family members. It's a great opportunity for those who want to learn more about their genetic health and take proactive steps in cancer prevention.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 18 years of age or older as documented in the medical record
• • 2. Speaks and reads English or Spanish as reported by the patient
• • 3. Patients who are currently receiving diagnostic, treatment, or follow-up care at New York Presbyterian/ Weill Cornell Medical Center, MD Anderson Cancer Center, Duke University or Columbia University.
• • 4. Patients with a newly diagnosed BRCA mutation presenting for consultation OR patients with known BRCA mutations who have been diagnosed with a confirmed deleterious (pathogenic) variant in BRCA1, or BRCA2 within the preceding 12 months as documented in the medical record
• • 5. BRCA1/2 mutation that is included on testing panel provided by the clinical genetic testing laboratory
• • 6. Patients who have at least one at risk relative who meets criteria for first degree relatives
• Exclusion Criteria:
• • 1. Is unwilling or unable to provide informed consent.
• • 2. Does not have email access.